Shares of CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) were up 4.4% during mid-day trading on Friday. The company traded as high as $26.76 and last traded at $26.8860. 249,429 shares changed hands during trading, a decline of 33% from the average session volume of 374,956 shares. The stock had previously closed at $25.75.
Wall Street Analyst Weigh In
CBLL has been the subject of several research reports. Canaccord Genuity Group raised their target price on CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. TD Cowen upped their price target on CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Raymond James Financial reiterated a “strong-buy” rating and issued a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. Finally, BTIG Research reissued a “buy” rating on shares of CeriBell in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.25.
View Our Latest Report on CBLL
CeriBell Stock Up 6.2%
The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.79 and a current ratio of 8.18. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -13.97 and a beta of 0.86. The stock’s fifty day moving average is $25.66 and its two-hundred day moving average is $21.15.
CeriBell (NASDAQ:CBLL – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). The company had revenue of $29.34 million for the quarter, compared to analyst estimates of $29.18 million. CeriBell had a negative net margin of 67.96% and a negative return on equity of 52.59%. Sell-side analysts predict that CeriBell, Inc. will post -2.05 earnings per share for the current fiscal year.
Insider Transactions at CeriBell
In related news, Director Josef Parvizi sold 25,000 shares of CeriBell stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $26.02, for a total transaction of $650,500.00. Following the transaction, the director owned 882,911 shares of the company’s stock, valued at $22,973,344.22. The trade was a 2.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CTO Raymond Woo sold 4,887 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $26.96, for a total value of $131,753.52. Following the sale, the chief technology officer owned 203,118 shares of the company’s stock, valued at $5,476,061.28. This trade represents a 2.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 139,859 shares of company stock valued at $3,554,775. Corporate insiders own 17.70% of the company’s stock.
Hedge Funds Weigh In On CeriBell
A number of hedge funds have recently bought and sold shares of CBLL. Goldman Sachs Group Inc. grew its stake in shares of CeriBell by 25.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 350,570 shares of the company’s stock worth $8,550,000 after acquiring an additional 70,261 shares in the last quarter. Entropy Technologies LP bought a new position in shares of CeriBell during the third quarter valued at about $803,000. Jump Financial LLC boosted its holdings in CeriBell by 153.2% during the third quarter. Jump Financial LLC now owns 93,705 shares of the company’s stock worth $2,285,000 after purchasing an additional 56,702 shares during the last quarter. Lisanti Capital Growth LLC purchased a new position in CeriBell during the third quarter worth about $4,466,000. Finally, Squarepoint Ops LLC purchased a new position in CeriBell during the second quarter worth about $638,000.
CeriBell Company Profile
Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.
See Also
- Five stocks we like better than CeriBell
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
